Development of a Highly Cardioselective Ultra Short-Acting β-Blocker, ONO-1101
Development of a Highly Cardioselective Ultra Short-Acting β-Blocker, ONO-1101
复制标题
开发高心脏选择性超短效 β 受体阻滞剂 ONO-1101
DOI：
10.1248/cpb.40.1462
复制
发表时间：
1992
影响因子：
1.7
通讯作者：
M. Kawamura
中科院分区：
文献类型：
--
作者：
S. Iguchi;H. Iwamura;M. Nishizaki;A. Hayashi;K. Senokuchi;K. Kobayashi;K. Sakaki;K. Hachiya;Y. Ichioka;M. Kawamura
一种新型的、对心脏具有高度选择性的超短效β阻滞剂ONO-1101已被开发出来，用于紧急治疗心动过速和在手术中更好地控制心率。这种药物在体内阻断β的活性大约是艾司洛尔的9倍，在体外对心脏的选择性是艾司洛尔的8倍。这种β阻断药物的活性持续时间很短，如果出现副作用，可以在停止给药后迅速恢复。它可以安全地用于患有急性心脏病的患者，并代表着心脏病治疗方面的重大进步。
A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This β-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.